18046-41-8 Usage
Derivative of benzimidazole
The compound is based on a bicyclic heterocyclic structure containing a benzene ring fused to an imidazole ring This describes the core structure of the compound and its relation to other benzimidazole derivatives.
Presence of a hydroxyl group
The benzimidazole ring has a hydroxyl group, making it a benzimidazole alcohol This highlights a specific functional group present in the compound.
Biological activities
Antimicrobial, antiviral, antitumor, and anti-inflammatory properties These are the potential therapeutic effects that benzimidazole derivatives, including 1H-Benzimidazole-2-ethanol,5-methyl-(9CI), may exhibit.
Limited research
The specific properties and potential applications of 1H-Benzimidazole-2-ethanol,5-methyl-(9CI) have not been extensively studied This indicates that more research is needed to fully understand the compound's capabilities.
Structural similarity to other benzimidazole derivatives
This suggests that 1H-Benzimidazole-2-ethanol,5-methyl-(9CI) may have similar pharmacological properties This provides a basis for hypothesizing potential uses based on related compounds.
Potential pharmaceutical and industrial uses
Further research is needed to determine the compound's applications in these fields This highlights the need for additional studies to explore the compound's potential in various industries.
Check Digit Verification of cas no
The CAS Registry Mumber 18046-41-8 includes 8 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 5 digits, 1,8,0,4 and 6 respectively; the second part has 2 digits, 4 and 1 respectively.
Calculate Digit Verification of CAS Registry Number 18046-41:
(7*1)+(6*8)+(5*0)+(4*4)+(3*6)+(2*4)+(1*1)=98
98 % 10 = 8
So 18046-41-8 is a valid CAS Registry Number.
InChI:InChI=1/C10H12N2O/c1-7-2-3-8-9(6-7)12-10(11-8)4-5-13/h2-3,6,13H,4-5H2,1H3,(H,11,12)
18046-41-8Relevant articles and documents
4-Isopropylchroman-3-ol derivatives
-
Paragraph 0349-0351, (2017/04/19)
The present invention relates to a novel 4-isopropylchroman-3-ol compound, a pharmaceutical composition comprising the novel compound as an effective component, and to an intermediate compound useful for synthesizing the compound. When administered to a patient with a drug causing toxicity, the novel 4-isopropylchroman-3-ol compound exhibits efficacy of reducing toxicity of the drug by reducing antagonism regarding a T-type calcium channel and/or activity of cytochrome P450 isozyme.
